Tyrosine kinase inhibitors (TKIs) have marked a turning point in the treatment of oncogene-addicted non-small cell lung cancer (NSCLC), offering unprecedented efficacy. Yet, most tumors eventually develop resistance and progress, often prompting discontinuation of the targeted agent and a switch to non-targeted therapi...
Francesca Piazza, Rishi Sharma, Alessandra Esposito et al.· Cancer Treatment Reviews· 0 citations
Lactate uptake through monocarboxylate transporter 1 (MCT1) is associated with aggressive disease in non-small cell lung cancer (NSCLC), but how lactate transport supports tumor metabolism remains incompletely understood. Integrating stable isotope tracing, metabolomics, and transcriptomics across patient tumors, anima...
Robert B. Cameron, Kristen E. Shema, Nathan Dubois et al.· bioRxiv· 0 citations
A multidisciplinary panel of oncology experts convened to review current evidence gaps, controversies, and unmet needs in the management of lung cancer, highlighting the need for prospective, head‐to‐head clinical trials.
N. Florez, S. Patel, R. Salgia et al.· Cancer· 1 citation
In a large international real-world study of non-small cell lung cancer, a multimodal explainable AI model outperformed established biomarkers for immunotherapy outcome prediction and improved physician decision-making.
A. Prelaj, V. Mišković, Matteo Sacco et al.· Nature Medicine· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.